A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis

Trial Profile

A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Umeclidinium (Primary)
  • Indications Hyperhidrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 05 Jan 2016 Planned end date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
    • 05 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top